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Regulation of cardiomyocyte DNA 
damage and cell death by the type 
2A protein phosphatase regulatory 
protein alpha4
Jonathan Cowan, Michael R. Longman & Andrew K. Snabaitis * 
The type 2A protein phosphatase regulatory protein alpha4 (α4) constitutes an anti-apoptotic protein 
in non-cardiac tissue, however it’s anti-apoptotic properties in the heart are poorly defined. To this 
end, we knocked down α4 protein expression (α4 KD) using siRNA in cultured H9c2 cardiomyocytes 
and confirmed the lack of DNA damage/cell death by TUNEL staining and MTT assay. However, α4 
KD did increase the phosphorylation of p53 and ATM/ATR substrates, decreased the expression of 
poly ADP-ribose polymerase and associated fragments. Expression of anti-apoptotic proteins Bcl-2 
and Bcl-xL was reduced, whereas expression of pro-apoptotic BAX protein did not change. Alpha4 
KD reduced basal H2AX Ser139 phosphorylation, whereas adenoviral-mediated re-expression of 
α4 protein following α4 KD, restored basal H2AX phosphorylation at Ser139. The sensitivity of 
H9c2 cardiomyocytes to doxorubicin-induced DNA damage and cytotoxicity was augmented by 
α4 KD. Adenoviral-mediated overexpression of α4 protein in ARVM increased PP2AC expression 
and augmented H2AX Ser139 phosphorylation in response to doxorubicin. Furthermore, pressure 
overload-induced heart failure was associated with reduced α4 protein expression, increased ATM/
ATR protein kinase activity, increased H2AX expression and Ser139 phosphorylation. Hence, this 
study describes the significance of altered α4 protein expression in the regulation of DNA damage, 
cardiomyocyte cell death and heart failure.
Cellular alpha4 (α4) was first cloned from B-lymphocytes as an immunoglobulin binding  protein1 and then later 
identified as tap42 in  yeast2. Several studies have shown α4 associates with all three type 2A protein phosphatase 
(T2APP) catalytic subunits in a non-catalytic  manner3–7, which has been reported to be  inhibitory5,8,9. However, 
a caveat for this inhibitory nature may depend on the identity of the  substrate10. Alpha4 plays a central role in 
maintaining the expression of T2APP catalytic subunits in numerous  tissues9,11, by controlling the ubiquitina-
tion state and levels of  PP2AC9,12,13. Hence, an additional consequence of the association between α4 and T2APP 
catalytic subunits, involves the “protection” of catalytic subunits from polyubiquitination and consequent 26S 
proteasome-mediated  degradation9. Interruption of this T2APP-α4 interaction by the genetic ablation of α4 
protein expression, has been shown to indirectly knockdown the expression of all T2APP catalytic subunits and 
induce apoptotic cell death in a number of cell  types9,14. Hence, α4 is considered to be an endogenous inhibitor 
of apoptosis, whose role in apoptotic cell death and heart failure is poorly understood.
Severe decompensated heart failure is characterised by the loss of left ventricular myocardial mass, thereby 
resulting in failure of pump function. Cell death can occur in an uncontrolled irreversible manner termed 
necrosis, or by a highly regulated process known as apoptosis, which is characterised by a cell committing to a 
series of cellular events that ultimately results in cell death. In the normal non-diseased heart the proportion of 
myocytes undergoing an apoptotic programme is very low (0.001–0.01%) compared to ~ 10 to 100-fold higher 
(0.08–0.25%) in the failing human  heart15,16. These observations suggest that although the levels of apoptosis in 
failing human hearts is low as a percentage of total myocardial mass, this chronic persistent level of apoptosis 
would contribute to the cumulative loss of myocytes and the development of a decompensated phenotype. 
Apoptosis plays a significant role in many human cardiovascular diseases ranging from myocardial infarction 
to end-stage heart  failure17–20. An observed commonality within the myocardial tissue from infarcted and failing 
hearts described in these studies is the presence of DNA damage, a known stimulus and hallmark of apoptosis. 
The ability of any tissue to repair DNA damage relies on the activity of a multitude of proteins that constitute 
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the DNA damage response (DDR), which ultimately preserves genomic stability. In general, the DDR involves 
the initial recognition of the DNA lesion followed by consequent activation of a signalling cascade to repair the 
DNA damage, of which there are many types and a double strand break (DSB) is considered the most deleteri-
ous in terms of cell  viability21. Central to the DDR are members of the phosphatidylinositol-3 kinase-related 
kinase (PIKK) family, which is a trinity of serine/threonine protein kinases comprised of ataxia telangiectasia 
mutated (ATM), ataxia telangiectasia and Rad3-related (ATR) and the DNA-dependent protein kinase catalytic 
subunit (DNA-PKcs). ATM and DNA-PKcs facilitate the repair of DSBs, whereas ATR is predominantly involved 
with resolving single stranded DNA structures at stalled DNA replication forks or resected  DSBs22. DNA DSBs 
formed as a consequence of genotoxic stress, are rapidly sensed and capped in the DNA domain of the DSB 
by the MRE11-RAD50-NBS1 (MRN)  complex23. The capping of the DSB by the MRN complex facilitates the 
recruitment and activation of ATM to the  DSB24. One of the primary events in response to DNA damage is the 
phosphorylation of the histone H2A variant H2AX at  Ser13925,26, which is considered a canonical target of the 
DDR PIKK family of  kinases27–31. A consequence of H2AX phosphorylation at Ser139 by ATM, is it forms dock-
ing sites both proximal and distal to the DSB  lesion29,32 to facilitate the recruitment of many other proteins that 
comprise the  DDR33. Activated ATM also phosphorylates the pro-apoptotic tumour suppressor protein p53 on 
multiple residues  (Ser1534–36,  Ser2036 and  Ser4636) in response to DNA damage. If the DNA damage is too severe 
so that genomic stability cannot be restored, the cell is then likely to undergo DNA damage-induced apoptosis 
and cell death. Apoptosis is in part regulated by a family of B cell chronic lymphocytic leukaemia (BCL)-2 
proteins, which is further been categorised into either anti- and pro-apoptotic sub-families of  proteins37. Severe 
heart failure is associated with elevated levels of pro-apoptotic BCL-2 associated x (Bax) protein  expression38 
and over expression of the BH4 domain of the anti-apoptotic BCL-2-related gene long isoform (Bcl-xL) protein 
has been shown to avert the onset of heart  failure39. This evidence suggests that both Bcl-xL and Bax members 
of the BCL-2 family of proteins may be involved in the pathogenesis of heart  failure40.
It has been known for many years that anti-cancer anthracycline agents such as doxorubicin can induce 
 cardiotoxicity41,42, which has since been confirmed by many  studies43,44 and is thought to occur via inhibition of 
topoisomerase 2β45. In non-cardiac cells, the overexpression of α4 protein protects against cell death induced by 
doxorubicin and nutrient  withdrawal9. However, the regulation of doxorubicin-induced cardiotoxicity by the 
T2APP-α4 protein signalling axis is undefined.
The DDR is driven by protein phosphorylation and evidence suggests that the T2APPs and α4 may play a 
modulatory  role9,46,47. In the current study, we report that the short-term (4 days) knockdown of α4 protein 
altered the expression and activity of proteins involved in the DDR and apoptosis, whereas sustained longer-
term (8 days) knockdown of α4 protein expression induced a significant loss of cell viability and subsequent 
cell death. Short-term α4 protein knockdown (i) increased the expression of pro-apoptotic Bax and decreased 
expression of anti-apoptotic Bcl-2 and Bcl-xL proteins and (ii) augmented the sensitivity of cardiomyocytes to 
doxorubicin-induced DNA damage and reduced cell viability. We also show that the loss of α4 protein down-
regulates H2AX Ser139 phosphorylation, which was rescued by the subsequent re-expression of α4 protein. In 
adult cardiomyocytes, the overexpression of α4 protein significantly enhanced the expression of PP2A, but not 
PP6C, whilst enhancing H2AX Ser139 phosphorylation in response to doxorubicin. End-stage heart failure 
induced by pressure overload for 9 weeks was associated with (i) decreased α4 protein expression, (ii) increased 
activity of ATM/ATR protein kinases and (iii) increased H2AX expression and Ser139 phosphorylation. This 
study illustrates the importance of maintaining α4 protein expression in the failing heart, to offset the induction 
of DNA damage and cell death by apoptosis.
Results
Activation of the DNA damage response (DDR) by α4 protein knockdown. The expression of α4 
protein was successfully knocked down over a period of 1–4 days by α4 targeted siRNA (Fig. 1a) using protocols 
previously  described11. The activity of kinases central to the DDR such as ATM and ATR was determined using 
an antibody recognising phosphorylated S/TQ motifs in proteins following 4 days of α4 KD. Figure 1b shows 
that several proteins underwent enhanced phosphorylation as indicated by arrows, however there were also 
proteins at a higher molecular weight (~ 150–200  kDa) that appeared to be dephosphorylated. Furthermore 
Fig. 1c demonstrates that total p53 expression, which can become elevated in response to genotoxic  stress48–50, 
remained unchanged despite being significantly (*P = 0.0148) phosphorylated at Ser15 in response to α4 KD. 
The expression of full length 116 kDa PARP, which is considered to be another protein involved in the DDR and 
Figure 1.  Regulation of the DNA damage response by α4 protein expression in cardiomyocytes. H9c2 
cardiomyocytes were transfected with either 50 nM non-targeting control (NTC) siRNA or 50 nM siRNA 
specific to rat α4 protein (siα4) for 1–4 days (n = 4) and the KD of α4 protein expression was confirmed by 
Western analysis using an antibody raised against human α4 (a). α4 protein expression was knocked down for 
4 days and Western analysis (short and long exposures) was used to probe samples (n = 3) with an antibody 
specific to phosphorylated S/TQG motifs within ATM/ATR substrates. Arrows indicate substrates whose 
phosphorylation status (n = 3) was elevated in response to α4 KD (b). The expression and phosphorylation 
(Ser15) of p53 were determined by Western analysis using rodent-specific antibodies raised against mouse 
p53 protein in samples following 4 days of α4 KD, n = 5 (c). The expression of PARP was determined by 
Western analysis (short and long exposures) following 1–4 days of α4 KD, n = 3. Arrows indicate full length 
PARP (116 kDa) and cleaved fragments (89 kDa and 24 kDa) (d). All data represents data mean values ± SEM 
and statistical significance vs. non-targeting control (NTC) was determined by a one-tailed Student’s T-test. 
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an enzyme stimulated by the presence of single and double strand  breaks51, was reduced following 4 days of α4 
KD (Fig. 1d). Interestingly, the abundance of the cleaved fragments (89 kDa and 24 kDa) was also reduced in 
response to α4 KD, thereby suggesting that PARP protein was not cleaved in response to α4 KD, but subject to 
total protein degradation. These data suggest that the knockdown of α4 protein in cardiomyocytes alters kinase 
activity and the expression of proteins involved in the DDR that is indicative of DNA damage.
Knockdown of α4 protein expression and cell viability. Figure 2a clearly illustrates that α4 protein 
expression was completely abolished after 4–8 days transfection with siRNA targeted against mRNA specific for 
rat α4 protein. This was associated with a progressive loss in cell viability, which reached significance (*P < 0.05) 
at 8 days post-transfection with α4 protein specific siRNA (Fig. 2b). Interestingly, the absence of a pathological 
effect following 4 days of α4 KD was observed despite our previous evidence demonstrating that the expression 
of all three T2APPs would have been almost completely abolished at this time  point11.
Knockdown of α4 protein expression sensitizes cardiomyocytes to doxorubicin-induced DNA 
damage and cell death. Despite the short-term (4 day) knockdown of α4 protein not inducing any sig-
nificant cell death or DNA damage, it was important to investigate whether α4 KD could modulate the DNA 
damage in response to genotoxic stress. To this end the topoisomerase 2β  inhibitor45 doxorubicin was used to 
induce DNA damage as indexed by the TUNEL assay (Fig. 3a). The quantification of TUNEL positive nuclei in 
Fig. 3b shows that DOX induced significant (*P < 0.0001) DNA damage which was significantly (**P = 0.001) 
exacerbated by the knockdown of α4 protein expression (Fig. 3b). Although Ser139 phosphorylation of H2AX 
was not significantly (P = 0.2121) phosphorylated at Ser139 in response to doxorubicin alone, it was significantly 
(*P = 0.0019) elevated by the knockdown of α4 protein (Fig. 3c). As shown in Fig. 3d, the DNA damage induced 
by doxorubicin was associated with a concomitant decrease in cell viability (*P < 0.0001) which was exacerbated 
Figure 2.  Long-term knockdown of α4 protein expression regulates DNA damage and cell death. H9c2 
cardiomyocytes were transfected with either 50 nM non-targeting control (NTC) siRNA or 50 nM siRNA 
specific to rat α4 protein (siα4) for 4, 6 and 8 days and the KD of α4 protein (n = 4) was confirmed by Western 
analysis (a). The viability of H9c2 cardiomyocytes following the KD of α4 protein expression for 4, 6 and 8 days 
was determined by MTT assay, data represents mean values ± SEM of 3 individual experiments (b). All data 
represents mean values ± SEM and statistical significance was determined by ANOVA followed by a multiple 
comparison Tukey’s modified test.
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Figure 3.  Alpha4 protein regulates doxorubicin-induced DNA damage and cytotoxicity in cardiomyocytes. H9c2 
cardiomyocytes were transfected with either 50 nM non-targeting control (NTC) siRNA or 50 nM siRNA specific to 
rat α4 protein (siα4) for 4 days. H9c2 cardiomyocytes were exposed to either DMEM vehicle control (CTR) or 1 µM 
doxorubicin (DOX) for 24 h on day 3. DNA fragmentation in H9c2 cardiomyocytes imaged at × 100 magnification 
was determined by TUNEL assay. Nuclei were stained with DAPI and samples were excited at 405 nm, whereas DNA 
fragmentation in samples was determined by fluorescein-conjugated TUNEL and excited at 488 nm. White arrows 
in merged images indicate positive TUNEL stained nuclei, n = 3, scale bar = 50 µm (a). DNA damage was quantified 
by counting DAPI stained nuclei followed by the number of TUNEL positive nuclei in 5 randomly selected regions 
of interest within the field of view, n = 3 (b). H9c2 cardiomyocytes were transfected with either 50 nM non-targeting 
control (NTC) siRNA or 50 nM siRNA specific to rat α4 protein (siα4) for 4 days. H9c2 cardiomyocytes were exposed 
to either DMEM vehicle control (CTR) or 100 nM doxorubicin (DOX) for 24 h on day 3. Phosphorylation of H2AX at 
Ser139 was then determined by Western analysis using a phosphospecific antibody raised against residues surrounding 
Ser139 of human H2AX, n = 4 (c) and cell viability was determined by MTT assay, n = 3 (d). All data represents mean 
values ± SEM and statistical significance was determined by ANOVA followed by a multiple comparison Tukey’s 
modified test. Expression of β-actin was used to confirm equal protein loading between samples.
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by the knockdown of α4 protein expression (**P = 0.0098). These data suggest that the absence of α4 protein 
expression, sensitizes cardiomyocytes to DNA damage induced by the genotoxic agent doxorubicin.
Modulation of Bcl-2 family protein expression by α4 protein knockdown. The knockdown of 
α4 protein expression for 4 days progressively altered the expression of pro-apoptotic Bax and anti-apoptotic 
Bcl-2 proteins (Fig. 4a). Although our data suggests that there was no significant change in Bax expression fol-
lowing 1–4 days of α4 KD (Fig. 4b), the expression of anti-apoptotic Bcl-2 was significantly decreased following 
2 (*P = 0.0162), 3 (*P = 0.0464) and 4 (*P = 0.0007) days of α4 KD (Fig. 4c). Hence, the Bax:Bcl-2 ratio was sig-
nificantly elevated at 3 (*P = 0.0037) and 4 (*P = 0.0177) days of α4 KD (Fig. 4d). Furthermore, the expression of 
the anti-apoptotic Bcl-2 family protein Bcl-xL was significantly (*P < 0.0001) reduced following 4 days of α4 KD 
(Fig. 4e). This suggests that even though there was no significant cell death following 4 days of α4 KD, there were 
however significant changes in the expression of proteins that can drive the apoptotic process.
Figure 4.  Alpha4 protein knockdown alters expression of BCL-2 family of pro- and anti-apoptotic proteins. 
H9c2 cardiomyocytes were transfected with either 50 nM non-targeting control (NTC) siRNA or 50 nM siRNA 
specific to rat α4 protein (siα4) for 1–4 days. The expression of Bax and Bcl-2 protein was determined by 
Western analysis using antibodies raised against human Bax and Bcl-2 protein (a). Quantification of Bax (b) and 
Bcl-2 (c) protein expression was determined by densitometry. The Bax:Bcl-2 ratio was calculated by dividing 
the Bax signal by the Bcl-2 signal (d). The expression of Bcl-xL was determined by Western analysis using an 
antibody raised against human Bcl-xL, in H9c2 cardiomyocytes transfected with either 50 nM non-targeting 
control (NTC) siRNA or 50 nM siRNA specific to rat α4 protein (siα4) for 4 days (e). Where appropriate, 
statistical significance was determined either by a one-tailed Student’s T-test or by ANOVA followed by a 
multiple comparison Tukey’s modified test. All data represents mean values ± SEM of 5 individual experiments. 
Expression of β-actin was used to confirm equal protein loading between samples.
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The phosphorylation of H2AX at Ser139 is regulated by α4 protein in cardiomyocytes. The 
phosphorylation status of H2AX at Ser139 has previously been reported to be upregulated by the knockdown 
of α4 protein  expression9 and is suggested to be a target for T2APPs in non-cardiac  cells52–54. The regulation of 
H2AX Ser139 phosphorylation by the T2APP-α4 signalling axis has not been determined in cardiac cells. To this 
end we knocked down the expression of α4 protein by siRNA, as previously described, but then re-expressed 
α4 protein using a novel adenovirus co-expressing EGFP and recombinant V5 -tagged rat α4 protein, under 
separate CMV promoters. The knockdown of α4 protein expression by siRNA was not altered by the subsequent 
infection with the control EGFP expressing adenovirus (Fig. 5a). Interestingly, the knockdown of α4 protein 
expression was associated with a loss of H2AX Ser139 phosphorylation and the subsequent infection with the 
control EGFP expressing adenovirus did not further alter the Ser139 phosphorylation status of H2AX (Fig. 5b). 
However, the re-expression of α4 protein to pre-knockdown levels, using the adenovirus expressing V5-tagged 
rat α4 protein (Fig. 5c) increased the phosphorylation status of H2AX at Ser139 (Fig. 5d). These data suggest that 
Ser139 phosphorylation of H2AX is regulated by α4 protein expression and appears to be independent of PP2AC 
expression in cardiomyocytes.
Alpha4 regulates H2AX phosphorylation in adult rat ventricular myocytes. Using protocols pre-
viously  described55, V5-tagged α4 protein was successfully overexpressed in ARVM using an alpha4-expressing 
adenovirus (Fig. 6a). Using subunit specific antibodies, the overexpression of α4 protein by adenoviral-medi-
ated gene transfer at 100 (*P = 0.0125) and 300 (*P = 0.0114) MOI, significantly increased the expression of the 
type 2A protein phosphatase catalytic subunit (Fig. 6b) but not the catalytic subunit of PP6 (Fig. 6c). Expos-
ing ARVM infected with the control EGFP expressing adenovirus to doxorubicin, induced a non-significant 
increase in Ser139 phosphorylation of H2AX. However, infecting ARVM with a α4 expressing adenovirus, did 
not alter basal H2AX phosphorylation, but did significantly (*P = 0.007) augment the phosphorylation of H2AX 
in response to doxorubicin (Fig. 6d). Hence, heterologous overexpression α4 protein sensitizes ARVM to DNA 
damage induced by doxorubicin.
DNA damage response in end-stage heart failure. Pressure overload-induced by trans-aortic con-
striction (TAC) for 9 weeks induced a significant (*P = 0.0001) increase (172.4%) in hypertrophic heart growth 
(Fig. 7a). M-mode transthoracic echocardiography revealed that TAC-operated hearts exhibited significantly 
compromised left ventricular diastolic (*P = 0.0003) and systolic (*P = 0.0001) function as shown in Fig.  7b, 
whereas Figs. 7c (*P < 0.0001) and 7d (*P < 0.0001) show significant reductions in both ejection fraction and 
fractional shortening, respectively. Western analysis of the TAC-operated failing myocardium revealed a non-
significant (P = 0.1092) > 50% reduction in α4 protein expression compared to hearts from SHAM-operated mice 
Figure 5.  Recovery of α4 protein expression regulates H2AX Ser139 phosphorylation in cardiomyocytes. 
H9c2 cardiomyocytes were transfected with either 50 nM non-targeting control (NTC) siRNA or 50 nM siRNA 
specific to rat α4 protein (siα4) for 4 days. On day 3, cardiomyocytes that were infected with either EGFP 
(a and b) or α4 (c and d) expressing adenoviruses at 30, 100 and 300 MOI for 1 h and harvested 24 h later. 
The expression of α4 and phosphorylation of H2AX at Ser139 was determined by Western analysis using an 
antibody raised against human α4 and residues surrounding Ser139 of human H2AX, respectively. Western 
immunoblots are representative of 3 individual experiments. Expression of β-actin and total H2AX was used to 
confirm equal protein loading between samples.
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(Fig. 7e). Using an antibody raised against phosphorylated S/TQG motifs within proteins targeted by the DDR 
ATM/ATR  kinases56,57, suggested an increase in ATM/ATR activity and the presence of DNA damage in the fail-
ing myocardium (Fig. 7f). Furthermore, levels of H2AX (Ser139) phosphorylation in SHAM and TAC-operated 
heart tissue was also determined, which was significantly (*P = 0.0367) elevated in hearts from TAC-operated 
mice. Interestingly, total non-phosphorylated H2AX expression was also determined and found also to be sig-
nificantly (*P = 0.0299) elevated in failing hearts from TAC-operated mice (Fig. 7g). These observations suggest 
Figure 6.  Alpha4 protein overexpression regulates H2AX Ser139 phosphorylation in adult rat ventricular 
myocytes. Western analysis using antibodies to human α4 protein and V5-tag were used to confirm α4 protein 
overexpression in ARVM using an adenovirus expressing V5-tagged α4 protein (0–300 MOI). Arrow indicates 
the expression of the heavier V5-tagged recombinant α4 protein, n = 4 (a). The expression of PP2AC (b) and 
PP6C (c) in response to adenoviral-mediated α4 protein overexpression was determined by Western analysis 
using T2APP subunit specific antibodies, n = 5. ARVM were infected with adenoviruses expressing either EGFP 
or α4 protein (300MOI) and treated with either DMEM vehicle control (CTR) or 100 nM doxorubicin (DOX) 
for 24 h. Phosphorylation of H2AX Ser139 was determined by Western analysis using an antibody raised against 
residues surrounding Ser139 of human H2AX, n = 6 (d). All data represents mean values ± SEM and where 
appropriate, statistical significance was determined by ANOVA followed by a multiple comparison Dunnett’s or 
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Figure 7.  α4 protein expression and DNA damage in pressure overload-induced end stage heart failure. 
The hypertrophic growth of the heart in response to SHAM or pressure overload induced by transaortic 
constriction (TAC) for 9 weeks, is expressed as heart weight (mg) normalized to tibia length (mm) (a). 
M-Mode transthoracic echocardiography was used to determine diastolic (EDD) and systolic (ESD) 
dysfunction (b), ejection fraction (c) and fractional shortening (d) in hearts following 9 weeks of SHAM or 
TAC surgery. Expression of α4 protein (e), phosphorylated ATM/ATR substrates (f), H2AX and H2AX Ser139 
phosphorylation (g) was determined in SHAM and TAC operated hearts by Western analysis using antibodies 
as described earlier. All data represents mean values ± SEM (6 SHAM/6 TAC) where statistical significance was 
determined where appropriate by a one or two-tailed Student’s T-test. Expression of α-actinin2 was used to 
confirm equal protein loading between samples.
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that pressure overload-induced failing myocardium expresses reduced levels of α4 protein and exhibits signifi-
cant DNA damage.
Discussion
The T2APP regulatory protein α4 was reported many years ago to be an endogenous inhibitor of apoptosis in 
non-cardiac  cells14 and its role in regulating the expression and activity of T2APPs was described several years 
 later9. However, a role for α4 protein in cardiac cells had been poorly defined, until our own recent work reported 
that α4 protein expression was not only elevated, but its association with PP6C was reduced in hypertrophied 
cardiac  tissue11. We and others have previously shown that the deletion of α4 protein expression indirectly 
decreases the expression of all three  T2APPs9,11, which in this study appeared to be tolerated for several days 
by cardiomyocytes, as determined by the absence of cell death. This current study describes the (i) incidence 
of DNA damage and (ii) the changes that occur in the expression/activity of proteins involved in the DDR and 
apoptosis during this period of α4 KD, when cell viability appeared to be maintained.
The knockdown of α4 protein expression has previously been shown to increase ATM autophosphorylation 
in non-cardiac  cells9. In support, our studies using an antibody raised against the ATM/ATR phosphorylation 
motif pS/TQG56,57, show that a number of ATM/ATR substrates became phosphorylated, thereby suggesting 
that ATM/ATR kinase activity was elevated in response to α4 KD. It is worth noting that this antibody may 
also have detected ATR-phosphorylated substrates. However, evidence suggests that the DDR kinase ATR is 
primarily recruited to single stranded DNA (ssDNA) at stalled replication forks by the association of its binding 
partner ATR interacting protein (ATRIP) with ssDNA bound replication protein A (RPA)22,58. Hence, it is likely 
that the phosphorylated substrates detected by the phospho-ATM/ATR substrate antibody, in response to α4 
KD, are those substrates predominantly targeted by the DDR kinase ATM. One such substrate is p53, which can 
be phosphorylated at Ser15 by ATM in response to DNA  damage34–36. In our study, α4 KD induced significant 
phosphorylation of p53 at Ser15, thereby implying that α4 KD induced a degree of DNA damage that stimulated 
the recruitment and activated ATM to the site of DNA damage. Furthermore, α4 KD induced the cleavage of 
full-length poly(ADP-ribose) polymerase (PARP), an enzyme that participates in the  DDR51. The cleavage of 
full length PARP results in the generation of two 89 kDa and 24 kDa fragments that contain the active site and 
DNA-binding domain of PARP,  respectively59–61. To our surprise, the cleaved 89 kDa and 24 kDa fragments 
were also lost, thereby suggesting a wholesale loss of PARP expression. Interestingly, PARP was recently identi-
fied as a ubiquitination target for the E3 ubiquitin ligase RNF144A, which is itself activated by DNA  damage62. 
This is important to the context of our study as activated RNF144A may ubiquitinate PARP for proteasomal 
 degradation63, which may explain the observed disappearance of PARP and it’s fragments in our study.
Alpha4 protein was described many years ago by the Thompson lab as an anti-apoptotic protein 14. As in our 
current study, they rapidly (48–72 h) deleted α4 protein using a variety of techniques, which induced significant 
cell death in a number of tissues. However, in the present study, there was an absence of DNA fragmentation and 
cell death, following 4 days of α4 protein expression knockdown by siRNA. However, longer-term knockdown 
(8 days) of α4 protein expression was associated with significant levels of DNA damage as indexed by terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assay and cell death (Supplementary 
Fig. S1 online). However, knockdown of α4 protein expression for 6 days was shown to induce significant TUNEL 
staining in the liver of α4-floxed mice injected with a Cre-recombinase expressing  adenovirus14. It does appear, 
as though cardiomyocytes may be more tolerant to the absence of α4 protein expression than non-cardiac cell 
types in which the anti-apoptotic properties of α4 protein have been studied.
Having determined that the knockdown of α4 protein expression induces DNA damage and cell death in 
cardiomyocytyes, next it was important to determine whether this could exacerbate the effects of a known cyto-
toxic agent. We have shown, as many other laboratories have done so, that doxorubicin induces significant levels 
of DNA damage. In addition, we demonstrate that this damage was exacerbated by the knockdown of cellular 
α4 protein expression, thereby sensitizing cardiomyocytes to not only doxorubicin-induced, but also hydrogen 
peroxide  (H2O2)-induced (see Supplementary Fig. S2 online) DNA damage. Interestingly, our data shows that the 
knockdown of α4 protein expression does not itself alter basal H2AX Ser139 phosphorylation (discussed later), 
but augments H2AX Ser139 phosphorylation and cytotoxicity in response to doxorubicin. This however is only 
partly supported by previous evidence suggesting that H2AX phosphorylation at Ser139 could be elevated by 
α4 KD in non-cardiac cells, but prolonged when induced by exposure to either doxorubicin or  camptothecin9. 
Hence, our evidence suggests that although the basal phosphorylation status Ser139 of H2AX is not regulated 
by the T2APP-α4 signalling complex, it does suggest that α4 KD can augment and sensitise cardiomyocytes to 
DNA damage induced by doxorubicin.
The altered expression levels of BCL-2 family anti-and pro-apoptotic proteins has been used to determine the 
apoptotic status of cells. The knockdown of α4 protein expression in our current study (i) increased the expression 
of the pro-apoptotic protein Bax and (ii) decreased the expression of anti-apoptotic Bcl-2, thereby increasing 
the Bax:Bcl-2 ratio which is suggestive of an increased apoptotic burden within these  cells64. Furthermore, the 
expression of the anti-apoptotic protein Bcl-xL was significantly decreased by α4 KD, which has been shown 
to offset the apoptotic burden when overexpressed in mouse embryonic  fibroblasts14. The increase in Bax and 
decrease in Bcl-xL expression is indicative of mitochondrial mediated intrinsic apoptosis, despite unaltered cell 
viability as determined by the mitochondrial MTT assay. It is possible that there may be a significant lag time 
between these changes and eventual cell death or that these changes are simply a bystander effect of α4 KD.
Several studies have proposed that Ser139 of H2AX is a T2APP substrate in non-cardiac  cells9,52,53,65. How-
ever, our data earlier in this study suggested that H2AX phosphorylation at Ser139 may not be regulated by the 
T2APP-α4 complex, which required further investigation. Our previous work has shown that the knockdown of 
α4 protein using identical protocols for a similar duration as in this current study, significantly downregulated 
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T2APP  expression11. To this end, we explored this by studying the effects of silencing α4 protein expression 
using siRNA followed by adenoviral-mediated re-expression of recombinant α4 protein, on H2AX Ser139 phos-
phorylation. As seen before in this study, α4 KD did not increase but in fact decreased basal H2AX Ser139 
phosphorylation and the adenoviral dose-dependent re-expression of recombinant α4 protein, back to pre-
silencing levels of expression, restored H2AX Ser139 phosphorylation. Our premise that H2AX Ser139 is not 
a T2APP target in cardiomyocytes was further supported by our observations in adult ventricular myocytes, 
where adenoviral-mediated over expression of α4 protein resulted in the increased expression of PP2AC, but not 
PP6C. Our data suggests that the regulation of PP2AC and PP6C by α4 is different, which is not the first time 
this has been  observed10. The observed increase in PP2AC expression in response to α4 protein overexpression 
is partially supported by evidence reported in HEK293 cells, whereby the heterologous expression of flag-tagged 
PP2AC was augmented by simultaneous expression of flag-tagged α4  protein9. Despite the overexpression of α4 
protein significantly elevating PP2AC expression, this did not decrease basal H2AX Ser139 phosphorylation, but 
actually augmented H2AX Ser139 phosphorylation in response to doxorubicin. Our current data suggests that 
knockdown or overexpression of α4 protein does alter basal H2AX Ser139 phosphorylation, but that Ser139 of 
H2AX is not a T2APP target in cardiomyocytes. The augmented H2AX Ser139 phosphorylation in response to 
doxorubicin, whilst altering α4 protein expression, implies a greater degree of DNA damage in those cells, which 
may itself be finely controlled by the expression levels of α4 protein.
To put this work into context we also investigated the expression of α4 protein, ATM/ATR kinase activity and 
phosphorylation of H2AX at Ser139 in hearts subjected to long-term pressure overload. Nine weeks of pressure 
overload induced a severe failing phenotype that was associated with a > 50% reduction in α4 protein expression. 
Even though this reduction was not statistically different compared to SHAM animals, it is worth considering 
that this reduction was a chronic change in α4 protein expression and not an acute response to a short lived 
stimulus. Hence reduced α4 expression for several weeks may have had deleterious consequences, despite not 
being statistically different from SHAM operated mouse hearts. A reduction in α4 protein expression in failing 
hearts was associated with increased myocardial ATM/ATR activity, which is indicative of a stimulated DDR in 
cardiac tissue subjected to long-term pressure overload-induced DNA damage. These data are not too dissimi-
lar to the data we observed when α4 protein expression was knocked down by siRNA in H9c2 cardiomyocytes 
earlier in our study. These data highlight the importance of understanding the role of the DDR in heart failure 
since recent evidence suggests that haplodeficient ATM expression accelerates the development of heart failure 
following myocardial  infarction66. In addition, a compromised DDR mediated by the ablation of XRCC1, an 
enzyme crucial to the repair of DNA single strand breaks, was reported to exacerbate hypertrophic growth and 
induce heart failure in response to pressure  overload67. Furthermore, the observed increase in H2AX Ser139 
phosphorylation in failing myocardium would be indicative of the DDR, but surprisingly we also observed an 
increase in total non-phosphorylated H2AX in failing myocardium. This increase in non-phosphorylated H2AX 
would have offset the observed increase in Ser139 phosphorylation. However, recent evidence suggests that the 
accumulation of non-phosphorylated H2AX at DNA damage lesions can occur in order to not only stabilise 
H2AX content at the lesion, but also to expand/amplify the DDR either side of the damaged  lesion68. Our data 
confirms that end-stage decompensated heart failure is associated with depressed α4 protein expression and 
significant DNA damage.
We have shown that the knockdown of α4 protein expression can induce ATM/ATR activation and p53 
phosphorylation, thereby suggesting the presence of non-cytotoxic levels of DNA damage and the DDR, but the 
absence of cell death in cardiomyocytes. However, prolonged α4 protein KD was shown to induce significant 
DNA damage and eventual cell death. Furthermore, the KD of α4 protein appeared to sensitise cardiomyo-
cytes to DNA damage induced by doxorubicin, which in itself eventually caused significant cell death, possibly 
through differential expression of BCL-2 anti- and pro-apoptotic factors. We also present two pieces of evidence 
which suggest that, unlike in non-cardiac cells, Ser139 of H2AX does not constitute a T2APP target. Firstly, the 
knockdown of α4 protein expression and the subsequent loss of T2APP expression did not increase basal Ser139 
phosphorylation and secondly enhanced basal PP2AC expression induced by over expression of α4 protein in 
adult myocytes, did not reduce basal H2AX Ser139 phosphorylation. Furthermore, our data also suggests that 
in adult cardiomyocytes, the regulation of PP6C expression by α4 protein is more complex than that of PP2AC. 
In addition, to contextualise these data, pressure overload induced end-stage decompensated heart failure was 
associated with reduced α4 protein expression and significant levels of DNA damage and active DDR. We there-
fore believe that H2AX Ser139 phosphorylation constitutes a novel biomarker of cardiomyocyte DNA damage. 
We have known for many years that cancer patients undergoing chemotherapy with DNA-damaging genotoxic 
agents, are predisposed to developing cardiac complications. This current study highlights the importance of 
understanding how a4 protein may modulate that DNA damage and may allow us to understand how to mitigate 
any chemotherapy-induced cardiac complications.
Materials and methods
Animal tissue (adult rat ventricular myocytes) used in this study was obtained in accordance with the UK Home 
Office Guidance on the Operation of the Animals (Scientific Procedures) Act 1986 (UK), the Directive of the 
European Parliament (2010/63/EU) and received approval by the local ethics review board at King’s College Lon-
don. Healthy animals were sacrificed by a schedule one procedure completed by a home office licensed individual 
such that animal suffering was categorised as minimal. The in vivo animal studies were carried out following 
guidelines set forth by the American Association for Accreditation of Laboratory Animal Care and the U.S. Public 
Health Service policy on Humane Care and Use of Laboratory Animals. All mouse studies were approved and 
supervised by the University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee.
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Materials. Antibodies. Sheep polyclonal anti-PP2AC and -PP6C antibodies were a kind gift from Dr BE 
Wadzinski, University of Vanderbilt and used as previously  described11,69. Rabbit polyclonal antibody to detect 
α4 protein (A300-471A) was purchased from Bethyl Laboratories (USA). Antibodies to detect Bax (#2772), Bcl-
xL (#2762), phosphospecific ATM/ATR substrate (#6966), IGBP1 (α4) (#5699), PARP (#9542), phosphospecific 
(Ser139) H2AX (#9718), H2AX (#2595), rodent-specific p53 (#32532), rodent-specific phosphospecific (Ser15) 
p53 (#12571) and V5-tag (#13202) were obtained from Cell Signaling Technology (USA). The antibody to detect 
Bcl-2 protein (#610538) was obtained from BD Transduction Laboratories (UK) and the rabbit polyclonal anti-
body to detect alpha actinin-2 (GTX103219) was purchased from GeneTex (USA). Antibodies to detect β-actin 
(sc-47778), HRP-conjugated mouse anti-goat (sc-2354) and donkey anti-sheep (sc-2916) secondary antibod-
ies were all purchased from Santa Cruz Biotechnologies (USA). HRP-conjugated donkey/goat anti-rabbit and 
sheep/horse anti-mouse secondary antibodies were purchased from Cell Signaling Technology (USA).
Short interfering RNA. ON-TARGETplus SMARTpool rat specific siRNA to α4 (cat#L-100452-02-0020), ON-
TARGETplus non-targeting control (NTC) pool siRNA (cat#D-001810-10-20) and DharmaFECT#1 were pur-
chased from GE Healthcare/Horizon Discovery (Dharmacon).
Methods. H9c2 cardiomyocyte cell culture. H9c2 cardiomyocytes were obtained from ATCC (#CRL-1446) 
and cultured as described  previously11. In brief, H9c2 cardiomyocytes cultured for α4 knockdown studies, were 
initially seeded at ~ 30% confluency and incubated with an appropriate amount of siRNA and maintained in cul-
ture for 1–8 days. Doxorubicin or  H2O2 mediated cytotoxicity was determined in H9c2 cardiomyocytes follow-
ing 4 days of α4 knockdown. H9c2 cardiomyocytes were also re-transfected with siRNA on day 4 when required 
for longer-term studies requiring α4 knockdown for > 4 days.
Isolation and cell culture of adult rat ventricular myocytes (ARVMs). ARVM were enzymatically isolated from 
the hearts of adult male Wistar rats (200–250  g, B and K Universal Ltd) as previously  described55. In brief, 
ARVM were isolated by collagenase-based enzymatic digestion and then allowed to rest for 2 h post-isolation to 
form a loose pellet, followed by brief centrifugation at 50 g. Storage medium was then removed and the ARVM 
pellet was resuspended in sterile cell culture media prior to being cultured in 6-well Nunclon dishes. Freshly 
isolated ARVM were then infected with the appropriate adenovirus and cultured for a further 24 h as described 
 previously55. ARVM were then appropriately treated and processed for Western analysis.
Knockdown of protein expression in H9c2 cardiomyocytes by siRNA. H9c2 cardiomyocytes were cultured as 
described  previously11. Cultured H9c2 cardiomyocytes were transfected with either 50 nM ON-TARGETplus 
non-targeting control (NTC) pool siRNA or 50 nM ON-TARGETplus SMARTpool rat α4 specific siRNA (siα4). 
Transfected H9c2 cardiomyocytes were incubated at 37 °C in 5%  CO2 for 1 to 8 days. The transfection medium 
was replaced and cells re-transfected every 4 days when silencing α4 protein expression for > 4 days. The cells 
were then lysed with 1 × Laemmli sample buffer for subsequent Western analysis.
Determination of cell viability by MTT assay. H9c2 cardiomyocytes were seeded at a density of 2 ×  104 cells 
per mL in a 96 well plate and at 30% confluency the cells were transfected with 50 nM non-targeting control 
(NTC) siRNA or rat α4 specific siRNA using DharmaFECT(#1) transfection reagent. Culture growth media was 
changed 24 h post-transfection and 3 days after transfection, cells were treated with either 1 µM doxorubicin or 
DMEM as a vehicle control for 24 h. For the MTT assay, the culture media was replaced with phenol red-free 
DMEM containing MTT (0.5 mg/mL). The samples were incubated at 37 °C in the dark for 3 h and the media 
was then removed and replaced with 100µL of DMSO. The plate was then shaken for 15 min, before reading the 
absorbance at 550 nm using an Infinite M200 PRO plate reader (TECAN, UK). Data was analysed using Magel-
lan data analysis software (Magellan, Taiwan).
Recovery of α4 protein expression by adenoviral‑mediated gene transfer. Adenoviruses to express EGFP alone or 
co-express EGFP and α4 protein were purchased from Vector Biolabs (USA). In brief, the adenoviruses expressed 
either rat specific α4 protein (AdV:α4) containing a C-terminal V5-tag and/or enhanced green fluorescent pro-
tein (EGFP) under a separate cytomegalovirus (CMV) promoter. When appropriate, the adenovirus which only 
expresses EGFP (AdV:EGFP) was used to control for any effects that may have been induced by adenoviral-
mediated gene transfer unrelated to the overexpression of α4 protein. The duration of adenoviral infection and 
calculation of the multiplicity of infection (MOI) was as previously  described55. For the α4 recovery experiments, 
α4 protein expression was initially knocked down for 4 days as described in the previous section, except that on 
the second day H9c2 cardiomyocytes were infected with either EGFP- or α4 protein-expressing adenoviruses at 
30, 100 or 300 MOI for 1 h. Cells were then harvested 48 h later for subsequent Western analysis.
Pressure overload‑induced murine end‑stage heart failure. Transaortic constriction (TAC) surgery was com-
pleted by Dr Brian Cooley (Core Director, Animal Surgery Core Laboratory) at the McAllister Heart Institute, 
University of North Carolina, USA. Under ketamine:xylazine anesthesia (100 mg:15 mg/kg, respectively; i.p.) 
the aortic arch was exposed through an incision made over the suprasternal notch, with muscle and thyroid 
retraction, and a slight medial incision of the cranial portion of the sternum. A 6–0 silk suture was passed around 
the aorta between the origin of the innominate and left carotid artery and tied around a 27-gauge blunted needle, 
with rapid removal of the needle to leave a constricting suture in place around the aorta. The peri-sternal muscu-
lature and skin were closed in two layers. Mice were maintained for 9 weeks during which 4 sessions of transtho-
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racic echocardiography were completed at 0 (preoperative), 3, 6 and 9 weeks post-surgery. Mice were then sacri-
ficed by cervical dislocation and hearts rapidly removed and frozen  (LN2) for subsequent tissue homogenisation.
M‑mode transthoracic echocardiography. Twelve C57BL/6 male mice (6 SHAM/6 TAC) were pre-trained using 
restraints on an inclined board (25 degrees) in the supine position (tail down) to allow for conscious acquisition 
and analysis of M-mode echocardiography. The thoracic area of the mouse was first prepared using a depila-
tion cream and a Doppler was used to image hearts for multiple 5-s intervals with a VisualSonics Vevo2100 
ultrasound system. Each echocardiography sessions lasted for no more than 10 min during which time the heart 
rate was monitored by the ultrasound system. Spatial resolution was 30 µm and the frame rate was 740 fps. Par-
asternal M-mode images were evaluated measuring left ventricular wall thicknesses and internal diameters at 
end-systole and end-diastole, with calculation of LV ejection fraction and fractional shortening.
Preparation of murine heart tissue homogenates. Whole mouse hearts were homogenised on ice, using a hand 
held borosilicate glass homogeniser (GPE Scientific) in ice-cold tissue lysis buffer containing; Tris–HCl (20 mM), 
NaCl (150 mM),  Na2EDTA (1 mM), EGTA (1 mM), NP-40 (1%), sodium deoxycholate (1%), sodium dodecyl 
sulphate (0.1%), sodium pyrophosphate (2.5 mM), beta-glycerophosphate (1 mM),  Na3VO4 (1 mM), leupeptin 
(1 µg/mL) and one mini protease inhibitor cocktail cOmplete (Roche Pharmaceuticals, UK), pH 7.5 at a ratio 
of 100 mg tissue/mL lysis buffer. The tissue homogenate was then centrifuged at 14,000 g at 4 °C for 30 min to 
remove any cellular debris and the supernatant removed, to which an appropriate volume of 3 × Laemmli sample 
buffer was added.
Western analysis. Western analysis was carried out as previously  described55,70. In brief, protein samples were 
separated by 6% to 15% SDS-PAGE, transferred to PVDF (0.2 µm or 0.45 µm pore size) or nitrocellulose mem-
branes and then probed with primary antibodies. Where appropriate, primary antibodies were detected using 
donkey anti-rabbit, anti-sheep or anti-goat; goat anti-rabbit; sheep or horse anti-mouse secondary antibodies 
(1:1000) linked to HRP. Specific protein bands were detected by enhanced chemiluminescence (GE Healthcare, 
UK) and band intensity was quantified using a calibrated GS-800 densitometer and Quantity One 1-D analysis 
software v4.6.2 (Bio-Rad, UK). Equal protein loading was determined either by quantifying the content of non-
phosphorylated protein (where appropriate), β-actin or alpha actinin-2 within each sample.
Determination of DNA damage by confocal microscopy. DNA damage was assessed by terminal deoxynucleoti-
dyl transferase (TdT)-mediated dUTP nick end labelling (TUNEL) of double strand breaks within DNA using 
a fluorescein-based in‑situ cell death detection kit (Roche Pharmaceuticals, UK). In brief, H9c2 cardiomyocytes 
were cultured onto pre-coated (ibiTreat) 35 mm µ-dishes (Ibidi, UK) and treated appropriately. Cardiomyocytes 
were then fixed using paraformaldehyde (4%) for 10 min at room temperature and briefly rinsed with phosphate 
buffered saline (PBS). Cardiomyocytes were permeabilised with PBS + Triton X-100 (0.1%) for 15 min at room 
temperature (RT) and then briefly rinsed with PBS. Cardiomyocytes were then incubated with PBS containing 
bovine serum albumin (1%) for 1 h at room temperature (RT). The TUNEL stain was prepared with “label solu-
tion” according to the manufacturer’s instructions and 50uL was added per µ-dish and incubated in a humidified 
incubator with 5%  CO2/95% air for 1 h at 37 °C. The dishes were then briefly rinsed with PBS at RT to which 
was added 50 µL of ProLong Diamond Antifade mountant with DAPI (Molecular Probes, UK) and a 19 mm 
coverslip (Thermo Scientific, UK). Dishes were left to cure overnight at RT in the dark. The acquisition of images 
was performed by exciting the prepared samples with laser lines 405 nm (DAPI stain) or 488 nm (TUNEL stain) 
using a Zeiss LSM800 laser scanning confocal microscope. Five randomly chosen regions of interest (ROI) per 
dish were imaged at a magnification of × 100. The DAPI stained nuclei were first counted in each ROI followed 
by TUNEL positive nuclei and the percentage of apoptotic nuclei was then calculated. TUNEL and DAPI stained 
Images were merged to determine the % of TUNEL positive nuclei.
Statistical analysis. Data are presented as mean ± SEM. Where appropriate, data were subjected to either 
an unpaired Student’s t-test or ANOVA (GraphPad Prism v8.2) to test for significant differences (P < 0.05) 
between groups and further multiple group statistical comparison was completed using either a Dunnett’s or 
Tukey’s modified t-test if required.
Data availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files).
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